Abstract
Porcine deltacoronavirus (PDCoV) is an emerging enteric pathogen that has recently been detected in humans. Despite this zoonotic concern, the antigenic structure of PDCoV remains unknown. The virus relies on its spike (S) protein for cell entry, making it a prime target for neutralizing antibodies. Here, we generate and characterize a set of neutralizing antibodies targeting the S protein, shedding light on PDCoV S interdomain crosstalk and its vulnerable sites. Among the four identified antibodies, one targets the S1A domain, causing local and long-range conformational changes, resulting in partial exposure of the S1B domain. The other antibodies bind the S1B domain, disrupting binding to aminopeptidase N (APN), the entry receptor for PDCoV. Notably, the epitopes of these S1B-targeting antibodies are concealed in the prefusion S trimer conformation, highlighting the necessity for conformational changes for effective antibody binding. The binding footprint of one S1B binder entirely overlaps with APN-interacting residues and thus targets a highly conserved epitope. These findings provide structural insights into the humoral immune response against the PDCoV S protein, potentially guiding vaccine and therapeutic development for this zoonotic pathogen.
| Original language | English |
|---|---|
| Article number | 5330 |
| Journal | Nature Communications |
| Volume | 15 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 22 Jun 2024 |
Bibliographical note
Publisher Copyright:© The Author(s) 2024.
Funding
We thank Tony Smits for technical support and Wentao Li for providing DCoV S1 constructs. This study was done within the framework of the research programme of the Netherlands Centre for One Health ( www.ncoh.nl ). This work was partially funded by the Corona Accelerated R&D in Europe (CARE) project. The CARE project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 101005077 (to B.J.B. and F.J.M.K.). The JU receives support from the European Union\u2019s Horizon 2020 research and innovation program, the European Federation of Pharmaceutical Industries Associations (EFPIA), the Bill & Melinda Gates Foundation, the Global Health Drug Discovery Institute, and the University of Dundee. The content of this publication reflects only the authors\u2019 views, and the JU is not responsible for any use that may be made of the information it contains.
| Funders | Funder number |
|---|---|
| Global Health Drug Discovery Institute | |
| European Federation of Pharmaceutical Industries and Associations | |
| University of Dundee | |
| Horizon 2020 Framework Programme | |
| Bill and Melinda Gates Foundation | |
| Innovative Medicines Initiative | 101005077 |
| Innovative Medicines Initiative |
Keywords
- Animals
- Antibodies, Neutralizing/immunology
- Antibodies, Viral/immunology
- CD13 Antigens/metabolism
- Coronavirus Infections/immunology
- Deltacoronavirus/immunology
- Epitopes/immunology
- HEK293 Cells
- Humans
- Protein Binding
- Protein Domains
- Spike Glycoprotein, Coronavirus/immunology
- Swine
- Swine Diseases/virology